Photocure and Artera Launch Joint Research on AI Bladder Cancer Test
Photocure ASA and Artera announced a research collaboration on June 8, 2026, to evaluate an AI-powered digital pathology test using data from Photocure's blue light cystoscopy registry. The project focuses on non-muscle invasive bladder cancer and aims to improve treatment selection.
ibtimes.co.ukPhotocure ASA and Artera announced a joint research initiative on June 8, 2026, to assess the ArteraAI Bladder Test using clinical data from Photocure's U.S. blue light cystoscopy registry. The collaboration will supply Artera with registry records to develop and validate multimodal AI biomarkers for patients with non-muscle invasive bladder cancer.
Researchers intend to measure the test's ability to predict disease progression and guide therapy choices.
The companies plan to pair blue light cystoscopy specimens with the AI test to determine tumor grade and stage while assessing suitability for specific drug treatments. The effort targets gaps in established biomarkers that currently limit individualized care.
Anders Neijber, Chief Medical Officer of Photocure, said the partnership seeks to combine imaging data with AI outputs to streamline decisions for pathologists and urologists. The project remains in the validation phase, with no timeline given for regulatory review or commercial release.
